强生公司已向美国食品药品监督管理局 (FDA) 提交了其与Protagonist Therapeutics合作开发的口服 IL-23 受体抑制剂icotrokinra用于治疗斑块状银屑病的的申请,目前正将开发重点转向炎症性肠病领域,并正准备开展 III 期临床试验。此前,新数据显示,该药对溃疡性结肠炎 (UC) 患者具有剂量依赖性获益,且安全性良好。IIb期积极结果在本周举行的欧洲胃肠病学联合组 ...
Source Link强生公司已向美国食品药品监督管理局 (FDA) 提交了其与Protagonist Therapeutics合作开发的口服 IL-23 受体抑制剂icotrokinra用于治疗斑块状银屑病的的申请,目前正将开发重点转向炎症性肠病领域,并正准备开展 III 期临床试验。此前,新数据显示,该药对溃疡性结肠炎 (UC) 患者具有剂量依赖性获益,且安全性良好。IIb期积极结果在本周举行的欧洲胃肠病学联合组 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.